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We reviewed the cases of 66 patients who underwent 67 tricuspid valve 
replacements with Carpentier-Edwards pericardial xenografts between 
April 1985 and January 1994. Average patient age at time of operation was 
52 years (range 8 to 71 years). Concomitant mitral or aortic valve 
replacements were performed in 46 patients. There were 10 operative 
deaths and 6 late deaths. Actuarial survival at 9 years was 75.4% -+ 5.7%. 
Prosthetic valve endocarditis occurred twice in one patient. Reoperations 
for tricuspid regurgitation and for concomitant procedures (maze opera- 
tion and repair for leak of the mitral prosthesis) were performed in two 
patients. In both cases, examination of the explanted prostheses howed 
that the tricuspid regurgitation was the result of nonstructural dysfunction 
caused by fibrous pannus formation on the cusps of the ventricular side. 
Among the survivors, 47 patients (92%) were in functional class I or II. 
Prosthetic valve function was studied by color Doppler echocardiography. 
Among 38 patients, tricuspid regurgitation more than grade 3/4 or 
transprosthetic gradient more than 5 mm Hg was found in 11. One patient 
had right heart failure and the others had no symptoms. In 10 years of 
experience with the Carpentier-Edwards pericardial xenograft, mortality 
and morbidity after tricuspid valve replacement were satisfactory. Echo- 
cardiographic examination revealed subclinical prosthetic dysfunction in 
35% of patients who were followed up for longer than 5 years, however, and 
we believe that these patients should receive careful follow-up. (J THORAC 
CARDIOVASC SURG 1996;111:605-12) 
B ecause the hemodynamic, anatomic, and hema- tologic characteristics of the right ventricle are 
different from those of the left ventricle, the clinical 
performance of a valve prosthesis in the tricuspid 
position should differ from that of a valve in the left 
side of the heart. Several authors have reported 
long-term results of the Carpentier-Edwards peri- 
cardial xenograft (CEPX), a second-generation bio- 
prosthesis, in the aortic and mitral positions. 1-3 
Little is known, however, regarding the clinical 
per formance of the CEPX in the tricuspid posi- 
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tion. This study represents our 10-year experience 
with the CEPX for tricuspid valve replacement  
(TVR).  
Patients and methods 
Patients. From April 1985 to January 1994, 67 CEPXs 
were implanted in the tricuspid position in 66 patients. 
The prostheses were sized 27 mm in 4 patients, 29 mm in 
6 patients, 31 mm in 38 patients, and 33 mm in 19 patients. 
An isolated procedure was performed in 13 patients. 
Additional procedures are shown in Table I. Concomitant 
mitral valve replacement (MVR), concomitant MVR and 
aortic valve replacement (AVR), and AVR with previous 
MVR and concomitant AVR were performed in 22, 20, 
and 4 patients, respectively. The prostheses used in the 
mitral or aortic positions were mainly mechanical valve 
prostheses. In two patients, the CEPX was used for 
concomitant MVR. 
TVR was performed with standard cardiopulmonary 
bypass and moderate systemic hypothermia. After com- 
pletion of the AVR and MVR procedures, the tricuspid 
valve was assessed. The valve was excised, except for a 
segment along the conduction bundle. In most patients, 
the CEPX was implanted with multiple everting mattress 
sutures with pledgets in the tricuspid anulus, except for a 
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Table I. Operative procedures 
Procedure(s) No. of patients 
Isolated TVR 13 
TVR with concomitant procedures 
MVR 20 
MVR + aortic repair 1 
MVR + shunt closure 1 
MVR + AVR 19 
MVR + AVR + shunt closure 1 
Mitral repair 3 
AVR + mitral repair 2 
AVR + shunt closure 1 
AVR* 1 
ASD closure 2 
PVR (CEPX) 1 
Pericardiectomy 1 
Maze 1 
MVR, Mitral valve replacement; AVR, aortic valve replacement; ASD, 
atrial septal defect; PVR, pulmonary vascular resistance. 
*This patient had undergone previous MVR. 
segment along the conduction bundle, where sutures were 
laid on the septal eaflet. 
Preoperative characteristics of the study population are 
shown in Table II. Age at operation ranged from 8 to 71 
years, with an average age of 52 years. In 94% of the 
patients, preoperative New York Heart Association 
(NYHA) functional class was III or IV. Previous cardiac 
operations had been performed once in 38 patients and 
twice in 6 patients. Previous TVR had been performed in 
,4 patients and previous tricuspid annuloplasty b modified 
DeVega or Kay methods had been performed in 17 
patients. The causes of the tricuspid valve lesions were as 
follows: Ebstein's anomaly (n = 12), tricuspid regurgita- 
tion (TR) caused after the repair of congenital nomalies 
(n = 2), infectious endocarditis (n = 1), congenital TR 
(n = 1), and degenerative disease (n = 1). In 50 cases, the 
patients had concomitant mitral valve disease. Obvious 
hemodynamic tricuspid stenosis with fusion of the com- 
missures had occurred in two patients. In the remaining 
cases, previous procedures for the tricuspid valve (TVR or 
extended tricuspid annuloplasty) had been performed or 
TR was caused by dilation of the tricuspid anulus and 
elongation of the chordae, probably as a result of mitral 
valve disease. Valvuloplasty was not effective in those 
cases. 
Fifty-one patients had preoperative atrial fibrillation 
and two patients had implanted pacemakers before TVR. 
The postoperative implantation of a pacemaker was re- 
quired in four patients. 
Postoperative follow-up. Surviving patients have been 
examined in the outpatient clinic at least once every 3 
months. All survivors have been followed up yearly by 
questionnaire. The patients who could not be contacted by 
questionnaire w re interviewed by telephone. One patient 
was unavailable for follow-up. We were successful in 
following up 98.5% of the patients. Follow-up duration 
ranged from 8 months to 9 years and 6 months. Mean 
follow-up duration among operative survivors was 4 years 
and 2 months, and this follow-up totaled 283 patient- 
years. 
Table II. Preoperative patient characteristics 
Age 
Mean _+ SD (yr) 52 -- 14 
Range (yr) 8-71 
Sex 
Male (n) 23 
Female (n) 44 
NYHA functional class 
II (n) 4 
III (n) 30 
IV (n) 33 
Cardiac rhythm 
Normal sinus (n) 14 
Atrial fibrillation (n) 51 
Pacemaker (n) 2 
Etiology of tricuspid lesion 
Ebstein's anomaly (n) 12 
Congenital (n) 3 
Infectious endocarditis (n) 1 
Degenerative disease (n) 1 
Related to mitral disease (n) 50 
Previous operation 
Primary (n) 23 
Secondary (n) 38 
Tertiary (n) 6 
TVR (n) 4 
TAP (n) 17 
PA systolic pressure (42 cases) 
Mean _+ SD (mm Hg) 44 _+ 22 
Range (ram Hg) 14-110 
Mean RA pressure (37 cases) 
Mean ± SD (ram Hg) 12 _+ 8 
Range (mm Hg) 2-32 
SD, Standard deviation; NYHA, New York Heart Association; TAP, 
tricuspid annuloplasty; PA,pulmonary artery; RA, right atrial. 
Definitions of events and methods of analyzing the 
results follow the guidelines published in this Journal. 4
Thromboembolism was restricted to pulmonary embo- 
lism, excluding systemic thromboembolism. The actuarial 
curves were constructed by standard nonparametric 
Kaplan-Meier methods. Results are presented with stan- 
dard error. 
Anticoagulant therapy. Warfarin anticoagulation was 
initiated as soon as oral administration became possible. 
The patients with isolated TVR or concomitant MVR 
with the CEPX received warfarin for as long as 3 months 
after implantation; it was discontinued thereafter. The 
patients with isolated TVR and atrial fibrillation and the 
patients who received mechanical valves in the aortic or 
mitral position were maintained with long-term warfarin 
therapy. The criteria for an adequate anticoagulation state 
ranged from 254% to 454% in prothrombin time, which is 
equivalent to 2.9 to 1.8 times the control prothrombin 
time international normalized ratio. 
Echocardiographic study. To evaluate prosthetic valve 
function, echocardiographic examination was performed 
in 39 patients (80% of all survivors who were followed up 
for longer than 1 year). Doppler echocardiographic scans 
were obtained with a phased-array two-dimensional sector 
scanner and color-flow imager (Toshiba SSH160A, 
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Fig. 1. Actuarial survival curve, including operative deaths. Numbers above the horizontal axis represent 
the number of patients eligible for analysis. 
SSA270A; Toshiba America Medical Systems, Tusten, 
Calif.). Continuous-wave systolic and diastolic spectral 
velocities across the tricuspid valve were recorded axially 
within the color-flow signals and were measured by 
planimetry. The TR flow signals were examined in the 
four-chamber apical view in a plane that maximized the 
color-flow area. Distance reached by regurgitant flow 
signals and area of regurgitant flow signals were mea- 
sured. The severity of regurgitation was graded according 
to the distance reached by the regurgitant signals and the 
area of regurgitant flow signals on a 4-point scale that was 
based on previous tudies from this center. 5'6 The mean 
transvalvular gradient was also estimated. 
Results 
The 10 operative deaths, including all hospital 
deaths, occurred (14.9%). All patients had combined 
mitral valve disease or mitral and aortic valve disease. 
Seven patients had undergone previous operation. The 
causes of operative death were as follows: multiorgan 
failure after persistent congestive heart failure (eight 
patients), cerebral bleeding (one patient), and uncon- 
trolled intraoperative bleeding (one patient). 
There were five late deaths. The causes of late 
death were as follows: congestive heart failure 
(two patients), cerebral bleeding (one patient), 
prosthetic valve endocarditis (one patient), and 
sudden death of unknown cause (one patient). 
The actuarial survival after 9 years, including 
operative deaths, was 75.4% ~ 5.7% (Fig. 1). 
Reoperation for tricuspid valve dysfunction and 
other complications was performed in two patients. 
One patient had undergone isolated TVR for Eb- 
stein's anomaly, and symptomatic paroxysmal trial 
fibrillation occurred 3 years after this operation. 
Although the patient did not have any signs of heart 
failure, the echocardiographic study represented 
grade 3 transvalvular TR. We replaced the CEPX 
with another CEPX at the time of maze operation 
for paroxysmal atrial fibrillation (case 1). The ex- 
planted CEPX is shown in Fig. 2. There was fibrous 
pannus on the ventricular side and tissue over- 
growth on the atrial side of the cusps, which corre- 
sponded to the location of septal and anterior 
leaflets of the native valve. Regurgitation occurred 
at the center of the prosthesis. The second patient 
underwent riple valve replacement 5 years after 
AVR and MVR. Hemolytic anemia occurred 8years 
after the second operation. Echocardiographic ex- 
amination revealed perivalvular leakage of the mi- 
tral prosthesis (Bj6rk-Shiley standard valve) and 
grade 3 TR with restricted cuspal motion. Transval- 
vular gradient through the tricuspid valve prosthesis 
was 3 mm Hg. We repaired the leakage of the mitral 
prosthesis and performed TVR with a mechanical 
valve prosthesis (case 2). The explanted CEPX is 
shown in Fig. 3. There was fibrous pannus on the 
ventricular side of the cusps, which corresponded to
the septal and the posterior leaflet of the native valve. 
We defined these two cases as nonstructural dysfunc- 
tion. Photomicrography of the explanted valve showed 
dense and thick fibrous pannus on the ventricular 
surface of the cusp. In the middle layer of the original 
prosthesis, mild separation of collagen bundles and no 
608 Nakano et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
March 1996 
Fig. 2. Gross view of the CEPX explanted 5 years after implantation (case 1). Left panel, ventricular 
aspect; right panel, atrial aspect; the left side of the prosthesis was located adjacent to the intraventricular 
septum in both aspects. Fibrous pannus is observed on the cusps of the ventricular side, which corresponds 
to the location of anterior and septal eaflet of the native valve. 
Fig. 3. Gross view of the CEPX explanted 8 years after implantation (case 2). Left panel, ventricular 
aspect; right panel, atrial aspect; the left side of the prosthesis was located adjacent to the intraventricular 
septum in both aspects. Fibrous pannus is observed on the cusps of the ventricular side, which corresponds 
to the septal and posterior leaflet of the native valve. 
calcification were observed. Fig. 4 presents the pho- 
tomicroscopic findings of the cusp in case 2. 
Endocarditis of the prosthetic valve in the tricus- 
pid position occurred twice in one patient who had 
undergone triple valve replacement. The event was 
fatal. Cerebral bleeding occurred in another patient 
who had undergone triple valve replacement. The 
aortic and mitral prostheses were St. Jude Medical 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 3 
Nakano et al. 609 
Fig. 4. Pathologic microscopic findings of the cusp in the same case shown in Fig. 2 (Masson's trichrome 
stain; original magnification ×4). Top, atrial side; bottom, ventricular side. There was dense and thick 
fibrous pannus on the ventricular side. In the middle layer of the original bioprosthesis, no calcification and 
mild separation of collagen bundles were observed. 
valves, and the patient received warfarin anticoagu- 
lation for the mechanical valves. This event was 
excluded from tricuspid valve-related events. There 
were no instances of structural deterioration, throm- 
bosed valves, or pulmonary embolism. The actuarial 
rate of freedom from valve-related events, including 
nonstructural dysfunction and prosthetic valve en- 
docarditis, was 71.3% _+ 20.8% at 9 years. These 
events and sudden unexplained eaths and opera- 
tive deaths at 9 years accounted for 59.6% + 17.6% 
of all patients having TVR (Fig. 5). 
Of the 51 patients who survived, 47 (92%) were in 
NYHA functional class I or II. Four patients (8%) 
were in NYHA functional class III. 
Echocardiographic examination represented grade 
3 TR in six patients. Transprosthetic gradient of more 
than 5 mm Hg with restricted cuspal motion was 
detected in two patients. Three patients had both 
TR and transprosthetic gradient of more than 5 mm 
Hg with restricted cuspal motion. All of these 
patients had been followed up for longer than 5 
years, and they represented 35% of all survivors who 
were followed up for longer than 5 years. Two of 
them underwent reoperation, as mentioned previ- 
ously. The other patients have been followed up 
medically. Only one patient had right heart failure, 
which was well maintained medically; the others 
were free of symptoms. Fig. 6 represents the actu- 
arial rate of freedom from structural deterioration 
(Fig. 6, a), nonstructural dysfunction (Fig. 6, b), and 
nonstructural p us subclinical valve dysfunction (TR 
or transprosthetic gradient more than 5 mm Hg with 
restricted cuspal motion detected by echocardiogra- 
phy; Fig. 6, c). At 9 years after operation, the 
actuarial rate of freedom from structural deteriora- 
tion was 100%, the actuarial rate of freedom from 
nonstructural dysfunction was 72.8% _4_- 21.1%, and 
the actuarial rate of freedom from nonstructural 
plus subclinical valve dysfunction was 24.3% + 
20.0%. 
Discussion 
TVR is not a common procedure because valve 
repair is preferred for the treatment of TR. In the 
same period as this series, tricuspid valvuloplasty, 
including 27 ring annuloplasty procedures, was per- 
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Fig. 5. Actuarial rates for freedom from valve-related vents (a) and valve-related vents plus operative 
deaths and sudden deaths (b). 
formed in 410 patients. In the patients who required 
TVR, the organic hange of the tricuspid valve was 
prominent or TVR or tricuspid annuloplasty had 
already been performed. 
The choice of a bioprosthesis for TVR has been 
advocated for two reasons: (1) A valve can be 
expected to be more durable in a low-pressure 
chamber than in the systemic circulation. (2) A high 
rate of valve thrombosis has been reported for 
mechanical prostheses in the tricuspid position. 
In the literature on long-term results of TVR with 
bioprostheses, several authors have reported on the 
first-generation bioprostheses. 7-9 Guerra and col- 
leagues 7 reviewed the cases of 45 patients with 
14-year follow-up. Actuarial freedom from struc- 
tural deterioration of a Hancock tricuspid porcine 
bioprostheses at14 years is 68% _ 13%. 8 Kawachi 
and associates s also reported excellent durability of 
the Hancock porcine bioprosthesis in the tricuspid 
position. Their actuarial freedom from structural 
valve failure at 10 years was 94% _+ 6%. Eng and 
colleagues 9 reported long-term results of the TVR 
with the Ionescu-Shiley valve in 73 patients. In their 
mean 9.6 years of follow-up (range from 4 to 18 
years), primary tissue failure occurred in only one 
patient. Seventy-nine percent of the survivors were 
in NYHA functional class I or II. These articles 
document excellent durability of bioprostheses in
the tricuspid position. 
The CEPX is a second generation bioprosthesis 
that uses bovine pericardium tanned with glutaral- 
dehyde. Because this feature, together with computer- 
aided cusp and stent design, resulted in excellent 
wear-testing performance compared with other bio- 
prostheses, the CEPX should be more durable than 
other bioprostheses. 1° Several authors demonstrated 
excellent clinical performance ofthis prosthesis n the 
aortic position 1-3 and even in the mitral position) In 
these series, no cusp tear occurred for as long as 7 
years; cusp tear did occur in series with the Ionescu- 
Shiley pericardial valve. TM 12 These results uggest that 
more durability can be expected of the CEPX than of 
first-generation bioprostheses. 
A high incidence of valve thrombosis after TVRs 
with mechanical valves has been reported. The type 
of prosthesis used in most of these studies was the 
Bj6rk-Shiley tilting-disc valve) 316 Regarding the 
bileaflet valve, currently used worldwide, the princi- 
pal author (K.N.) saw 39 adult cases of TVR with 
the St. Jude Medical valve in another institution. 17
In the 14-year follow-up period, there was only one 
thrombosed valve (0.67% per patient-year) under 
conditions of proper anticoagulation. These results 
suggest that the incidence of valve thrombosis after 
TVR with the low-profile St. Jude Medical valve 
may be lower than that with the Bj6rk-Shiley valve. 
In that series, the actuarial rate of freedom at 14 
years from all operative deaths, all valve-related 
deaths (including sudden unexpected death), and all 
nonfatal valve-related morbid events was 80.5% + 
6.7%. In the study reported here, the actuarial rate 
of freedom at 10 years from the same events was 
58.2% + 17.3%. Both curves were not statistically 
significant. 
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Fig. 6. Actuarial rates for freedom from structural deterioration (a), nonstructural dysfunction (b), and 
nonstructural dysfunction plus subclinical dysfunction detected by Doppler echocardiography (c). 
The pathologic findings of both explanted CPEX 
valves demonstrated fibrous pannus formation in 
the ventricular side of the cusps, which made the 
cusps shrink and caused TR. The macroscopic find- 
ings did not demonstrate calcification and sclerotic 
change of the cusps. Cohen and colleagues is exam- 
ined Hancock porcine bioprostheses implanted si- 
multaneously in six patients and explanted 62 to 140 
months later. The degenerative changes were more 
extensive for the prostheses in the mitral position 
than for those in the tricuspid position. Thrombus 
formation was observed on the ventricular aspects of 
the bioprosthetic cusps in one valve in the mitral 
position and in four valves in the tricuspid position. 
Guerra and colleagues 7 reported morphologic ex- 
amination of explanted porcine bioprostheses in
their experience with nine reoperation cases. The 
prostheses explanted from the tricuspid position had 
lower degrees of calcification and less severe struc- 
tural change than did those simultaneously ex- 
planted from the mitral position. The finding pecu- 
liar to the tricuspid position, not observed in 
explants from the mitral position, was the presence 
of fibrous pannus on the ventricular side, growing 
into one or more sinuses and impairing pliability of 
the corresponding cusp. These findings correspond 
with those observed in our series. 
The pannus formation, interpreted as organized 
thrombotic material, may be related to the anatomic 
and hemodynamic characteristics of the right ven- 
tricle. Because the right ventricle is wedge shaped in 
configuration, the prosthetic usps adjacent o the 
sewing cuff easily might touch the remnant of the 
native valve and subvalvular component of the tri- 
cuspid valve, resulting in thrombus formation and 
tissue overgrowth. Further, lower pressure and 
lower flow velocity of blood in the right ventricle 
could increase the thrombogenicity of the xenograft. 
Even though the patients had not reported any of 
the symptoms of heart failure, echocardiographic 
studies revealed a high incidence of TR and trans- 
valvular gradients. In most cases of TR, the regur- 
gitant flow was detected near the center of the 
prosthesis and restricted motion was observed in 
one or two cusps. Echocardiographic information is 
limited in dearly explaining the cause of these subclin- 
ical valve dysfunctions. The study of explanted CEPX 
valves in this series, however, suggests hat most of the 
tricuspid bioprosthetic dysfunction i the intermediate 
period after operation may be caused by pannus 
formation on the cusps of the bioprosthesis, not by 
degenerative changes of the cusps. 
Of the patients in whom TR or transprosthetic 
gradient was detected by echocardiography (nine, 
excluding two patients who underwent reoperation), 
eight were in NYHA functional class I or II. One 
patient had a history of congestive heart failure 6 
years after MVR and TVR. Since then, however, 
this heart failure has been well controlled medically. 
None of these nine patients required replacement of
the tricuspid CEPX. 
In conclusion, in our 10-year experience with the 
CEPX, the mortality and morbidity after TVR were 
satisfactory. Echocardiographic examination re- 
6 1 2 Nakano et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
March 1996 
vea led subcl inical  prosthet ic  dysfunct ion in 35% of 
pat ients  who  were  fo l lowed up for longer  than 5 
years, however ,  and we bel ieve that  these pat ients  
need  careful  fo l low-up. 
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